Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort.

Eder L, Chandran V, Schentag CT, Shen H, Cook RJ, Gladman DD.

Rheumatology (Oxford). 2010 Jul;49(7):1361-6. doi: 10.1093/rheumatology/keq091. Epub 2010 Apr 12.

PMID:
20385615
2.

Axial psoriatic arthritis: update on a longterm prospective study.

Chandran V, Barrett J, Schentag CT, Farewell VT, Gladman DD.

J Rheumatol. 2009 Dec;36(12):2744-50. doi: 10.3899/jrheum.090412. Epub 2009 Nov 2.

PMID:
19884276
3.

Occurrence and correlates of fatigue in psoriatic arthritis.

Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD.

Ann Rheum Dis. 2009 Oct;68(10):1553-8. doi: 10.1136/ard.2008.098202. Epub 2008 Oct 17.

PMID:
18930991
4.

Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting.

Chandran V, Schentag CT, Gladman DD.

J Rheumatol. 2008 Oct;35(10):2069-70; author reply 2070. No abstract available.

PMID:
18843760
5.

Cardiovascular morbidity in psoriatic arthritis.

Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT.

Ann Rheum Dis. 2009 Jul;68(7):1131-5. doi: 10.1136/ard.2008.094839. Epub 2008 Aug 12.

PMID:
18697777
6.

Familial aggregation of psoriatic arthritis.

Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugarajah S, Toloza SM, Rahman P, Gladman DD.

Ann Rheum Dis. 2009 May;68(5):664-7. doi: 10.1136/ard.2008.089367. Epub 2008 Jun 4.

PMID:
18524791
7.

Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS).

Gladman DD, Schentag CT, Tom BD, Chandran V, Brockbank J, Rosen C, Farewell VT.

Ann Rheum Dis. 2009 Apr;68(4):497-501. doi: 10.1136/ard.2008.089441. Epub 2008 Apr 29.

PMID:
18445625
8.

Prevalence of malignancy in psoriatic arthritis.

Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD.

Arthritis Rheum. 2008 Jan;58(1):82-7. doi: 10.1002/art.23185.

9.

Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort.

Chandran V, Schentag CT, Gladman DD.

J Rheumatol. 2008 Mar;35(3):469-71. Epub 2007 Dec 15.

PMID:
18085735
10.

Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis.

Chandran V, O'Shea FD, Schentag CT, Inman RD, Gladman DD.

J Rheumatol. 2007 Dec;34(12):2463-5. Epub 2007 Nov 15.

PMID:
18050375
11.

Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.

Chandran V, Schentag CT, Gladman DD.

Arthritis Rheum. 2007 Dec 15;57(8):1560-3. No abstract available.

12.

Improved survival in psoriatic arthritis with calendar time.

Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD.

Arthritis Rheum. 2007 Aug;56(8):2708-14.

13.
14.

The long-term use of azathioprine in patients with psoriatic arthritis.

Lee JC, Gladman DD, Schentag CT, Cook RJ.

J Clin Rheumatol. 2001 Jun;7(3):160-5.

PMID:
17039121
15.

Predictors for radiological damage in psoriatic arthritis: results from a single centre.

Bond SJ, Farewell VT, Schentag CT, Gladman DD.

Ann Rheum Dis. 2007 Mar;66(3):370-6. Epub 2006 Aug 17.

16.

Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases.

Johnson SR, Glaman DD, Schentag CT, Lee P.

J Rheumatol. 2006 Jun;33(6):1117-22.

PMID:
16622903
17.

Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity.

Bond S, Farewell VT, Schentag CT, Lawless JF, Gladman DD.

J Rheumatol. 2005 Dec;32(12):2364-7.

PMID:
16331765
18.

Clinical and radiological damage in psoriatic arthritis.

Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD.

Ann Rheum Dis. 2006 Apr;65(4):478-81. Epub 2005 Aug 26.

19.

Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach.

Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD.

Arthritis Rheum. 2005 Jun 15;53(3):404-9.

20.

Autoantibodies in biological agent naive patients with psoriatic arthritis.

Johnson SR, Schentag CT, Gladman DD.

Ann Rheum Dis. 2005 May;64(5):770-2.

21.

Dactylitis in psoriatic arthritis: a marker for disease severity?

Brockbank JE, Stein M, Schentag CT, Gladman DD.

Ann Rheum Dis. 2005 Feb;64(2):188-90. Epub 2004 Jul 22.

22.

Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.

Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD.

Ann Rheum Dis. 2004 Feb;63(2):156-61.

23.

CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis.

Rahman P, Bartlett S, Siannis F, Pellett FJ, Farewell VT, Peddle L, Schentag CT, Alderdice CA, Hamilton S, Khraishi M, Tobin Y, Hefferton D, Gladman DD.

Am J Hum Genet. 2003 Sep;73(3):677-81. Epub 2003 Jul 23.

24.

HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls.

Gladman DD, Farewell VT, Rahman P, Schentag CT, Pellett F, Ng CM, Wade JA.

Hum Immunol. 2001 Nov;62(11):1239-44.

PMID:
11704286
25.

Remission in psoriatic arthritis.

Gladman DD, Hing EN, Schentag CT, Cook RJ.

J Rheumatol. 2001 May;28(5):1045-8.

PMID:
11361187
26.

Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis.

Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD.

J Rheumatol. 2001 May;28(5):1041-4.

PMID:
11361186
27.

Accuracy of self-reported family history in psoriatic arthritis.

Rahman P, Beaton M, Schentag CT, Gladman DD.

J Rheumatol. 2000 Mar;27(3):824-5. No abstract available.

PMID:
10743838
28.

Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis.

Rahman P, Schentag CT, Beaton M, Gladman DD.

Clin Exp Rheumatol. 2000 Jan-Feb;18(1):7-12.

PMID:
10728438
29.

Hyperuricemia in psoriatic arthritis: prevalence and associated features.

Bruce IN, Schentag CT, Gladman DD.

J Clin Rheumatol. 2000 Feb;6(1):6-9.

PMID:
19078442
30.

Excessive paternal transmission in psoriatic arthritis.

Rahman P, Gladman DD, Schentag CT, Petronis A.

Arthritis Rheum. 1999 Jun;42(6):1228-31.

31.

Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis.

Rahman P, Schentag CT, Gladman DD.

Arthritis Rheum. 1999 Apr;42(4):822-3. No abstract available.

32.

Dysphagia in individuals with no history of bulbar polio.

Dowhaniuk M, Schentag CT.

Ann N Y Acad Sci. 1995 May 25;753:405-7. No abstract available.

PMID:
7611657
33.

Re-examining the concept of severity in traumatic brain injury.

Wong PP, Dornan J, Keating AM, Schentag CT, Ip RY.

Brain Inj. 1994 Aug-Sep;8(6):509-18.

PMID:
7527268
34.

Statistical profile of traumatic brain injury: a Canadian rehabilitation population.

Wong PP, Dornan J, Schentag CT, Ip R, Keating M.

Brain Inj. 1993 Jul-Aug;7(4):283-94.

PMID:
8358402
35.

Predictive value of short-term growth using knemometry in a large population of healthy children.

Dean HJ, Schentag CT, Winter JS.

Acta Paediatr Scand. 1990 Jan;79(1):57-63.

PMID:
2316361
36.

The effect of leg position on knemometric measurements of lower leg length.

Schentag CT, Dean HJ, Winter JS.

Hum Biol. 1989 Apr;61(2):263-9.

PMID:
2767674

Supplemental Content

Loading ...
Support Center